Michael Boyer
Clinical Professor
Oncology
The University of Sydney
Australia
Biography
Following his specialty training in medical oncology at Royal Prince Alfred and Westmead Hospitals, Professor Boyer was a Research Fellow and Clinical Fellow at the Ontario Cancer Institute and Princess Margaret Hospital in Toronto, Canada, where he completed his PhD on cell biology. He was on the senior staff of the Sydney Cancer Centre and Royal Prince Alfred Hospital from 1993 to 2013, at which time he joined the newly opened Chris O’Brien Lifehouse. In addition to his clinical roles, he has held senior administrative positions during that time including Head of Department of Medical Oncology at Royal Prince Alfred Hospital, Director of the Sydney Cancer Centre, and Area Director of Cancer Services for the Sydney South West Area Health Service. His clinical interests are in the management of thoracic malignancies and head and neck cancers, His research training includes a laboratory PhD at the University of Toronto between 1990 and 1993. His more recent major research interest is in clinical trials of new agents in the management of lung cancer and mesothelioma. He is the author of over 145 publications, has given numerous national and international presentations, both invited and selected from abstract submission, and is actively involved in the lung cancer community. He chaired the scientific advisory committee of the Australasian Lung Cancer Trials Group between 2004 and 2011, and was the conference Co-President for the 15th World Conference on Lung Cancer held in Sydney in 2013. He is currently a member of the Board of Directors of the International Association for the Study of Lung Cancer.
Research Interest
Lung cancer Head and neck cancer
Publications
-
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
-
Paraneoplastic cerebellar ataxia with central hypoventilation.
-
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.